Does a person with a Body Mass Index (BMI) of 38.45 and obstructive sleep apnea (OSA) have morbid obesity?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Does a BMI of 38.45 with Obstructive Sleep Apnea Constitute Morbid Obesity?

Yes, a person with a BMI of 38.45 and obstructive sleep apnea meets criteria for morbid obesity, as they have Class II obesity (BMI 35-39.9) with a significant obesity-related comorbidity (OSA), which qualifies them for consideration of advanced weight management interventions including bariatric surgery evaluation.

Classification of Obesity by BMI

The World Health Organization classification system defines obesity severity based on BMI thresholds 1:

  • Class I obesity: BMI 30-34.99 kg/m²
  • Class II obesity: BMI 35-39.99 kg/m²
  • Class III obesity: BMI ≥40 kg/m²

A BMI of 38.45 kg/m² places this individual in Class II obesity 1.

Definition of Morbid Obesity in Clinical Context

While "morbid obesity" is not a formal WHO classification term, it is clinically used to describe obesity severe enough to cause significant health complications or warrant aggressive intervention 1. The term traditionally applies to:

  • BMI ≥40 kg/m² (Class III obesity), OR
  • BMI ≥35 kg/m² with severe obesity-related comorbidities such as type 2 diabetes, hypertension, heart failure, or obstructive sleep apnea 1

This patient meets the second criterion with a BMI of 38.45 kg/m² and documented OSA 1.

OSA as a Severe Obesity-Related Comorbidity

Obstructive sleep apnea is explicitly recognized as a severe obesity-related medical complication that elevates the clinical significance of obesity 1:

  • At least 70% of OSA patients are obese, and the incidence of OSA among morbidly obese patients is 12- to 30-fold higher than in the general population 2, 3
  • OSA results from anatomical changes including increased pharyngeal soft tissue deposition due to excess adiposity 1
  • OSA is associated with increased cardiovascular morbidity and mortality, metabolic syndrome, hypertension, and sudden cardiovascular death 1, 2, 3

Clinical Implications and Treatment Thresholds

The presence of OSA with Class II obesity has specific treatment implications that distinguish this from uncomplicated obesity 1:

Bariatric Surgery Eligibility

  • Bariatric surgery should be considered for patients with BMI ≥35 kg/m² who have severe obesity-related complications such as OSA 1
  • The American Thoracic Society recommends referral for bariatric surgery evaluation for patients with OSA and BMI ≥35 kg/m² whose weight has not improved despite comprehensive lifestyle interventions 1
  • This patient's BMI of 38.45 kg/m² with OSA meets established criteria from the 1991 National Institutes of Health consensus conference for bariatric surgery consideration 1

Pharmacotherapy Consideration

  • Anti-obesity pharmacotherapy evaluation is suggested for patients with OSA and BMI ≥27 kg/m² who fail lifestyle interventions and have no contraindications including active cardiovascular disease 1

Weight Loss Impact on OSA

  • Weight reduction is a critical therapeutic intervention, as diet-based weight loss can reduce apnea-hypopnea index (AHI) by approximately 44%, while surgical weight loss can reduce AHI by approximately 77% 4
  • Bariatric surgery in morbidly obese OSA patients can achieve mean AHI reductions from 40 to 7 events per hour (80% reduction) 5

Important Clinical Caveats

BMI Limitations

  • BMI does not distinguish between lean and fat mass, and individuals with high lean body mass may be misclassified 1
  • However, in the context of documented OSA, this limitation is less relevant as the presence of a severe obesity-related comorbidity confirms clinically significant excess adiposity 1

Comprehensive Assessment Needed

  • Beyond BMI, waist circumference (≥102 cm for men, ≥88 cm for women) should be measured as a marker of visceral adiposity and cardiometabolic risk 1
  • Screen for additional obesity-related comorbidities including type 2 diabetes, hypertension, nonalcoholic fatty liver disease, and cardiovascular disease 1
  • OSA severity should be quantified by polysomnography with AHI measurement 1

Treatment Priority

  • Weight management through comprehensive lifestyle intervention (reduced-calorie diet, exercise/increased physical activity, and behavioral counseling) should be the initial approach 1
  • The relationship between obesity and OSA is bidirectional and complex, with obesity exacerbating OSA and OSA potentially contributing to weight gain through metabolic dysregulation 1, 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Obstructive sleep apnea in the obese.

World journal of surgery, 1998

Guideline

Obesity and Central Sleep Apnea: The Connection

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.